Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Apr;36(4):401-410.
doi: 10.1007/s40263-022-00910-8. Epub 2022 Mar 13.

Risdiplam: A Review in Spinal Muscular Atrophy

Julia Paik  1
Affiliations
Review

Risdiplam: A Review in Spinal Muscular Atrophy

Julia Paik. CNS Drugs. 2022 Apr.

Abstract

Risdiplam (Evrysdi®) is the first oral drug developed to treat spinal muscular atrophy (SMA) and is approved in multiple countries worldwide. It is approved for the treatment of SMA in patients aged ≥ 2 months in the USA and the EU, with this approval further specified in the EU for the treatment of 5q-autosomal recessive SMA with a clinical diagnosis of SMA types 1, 2, or 3 or with one to four survival motor neuron 2 (SMN2) copies. As an SMN2 pre-mRNA splicing modifier, risdiplam increases the production of full-length SMN protein, the lack of which drives the pathophysiology of SMA. In phase 2/3 clinical trials, risdiplam significantly improved motor function in infants with SMA type 1 and in patients aged 2-25 years with SMA types 2 or 3. These motor improvements were maintained with up to 2 years of treatment with risdiplam. Risdiplam was generally well tolerated, with a favourable benefit to risk balance. As an oral drug, risdiplam provides a convenient and useful treatment option across a broad range of patient ages and subtypes of SMA.

Plain language summary

Patients with spinal muscular atrophy (SMA) have insufficient levels of survival motor neuron (SMN) protein due to a defect in the SMN1 gene. The SMN2 gene is also able to produce some SMN protein, but not to the amount required to maintain adequate muscle function and form. Risdiplam (Evrysdi®) is a drug that targets SMN2 to improve the production of viable SMN protein and the first oral medication approved for the treatment of SMA. In the FIREFISH and SUNFISH clinical trials, risdiplam improved motor function in patients of all ages, with improvements maintained after 24 months of treatment. Risdiplam was generally well tolerated in these trials, with a favourable benefit to risk balance. As an orally administered treatment, risdiplam provides a convenient and useful treatment option across a broad range of patient ages and subtypes of SMA.

PubMed Disclaimer

References

    1. Darras BT. Spinal muscular atrophies. Pediatr Clin N Am. 2015;62(3):743–66. - DOI
    1. Alias L, Bernal S, Fuentes-Prior P, et al. Mutation update of spinal muscular atrophy in Spain: molecular characterization of 745 unrelated patients and identification of four novel mutations in the SMN1 gene. Hum Genet. 2009;125(1):29–39. - DOI
    1. Schorling DC, Pechmann A, Kirschner J. Advances in treatment of spinal muscular atrophy: new phenotypes, new challenges, new implications for care. J Neuromuscul Dis. 2020;7(1):1–13. - DOI
    1. Verhaart IEC, Robertson A, Wilson IJ, et al. Prevalence, incidence and carrier frequency of 5q-linked spinal muscular atrophy: a literature review. Orphanet J Rare Dis. 2017;12(1):124. - DOI
    1. Dominguez CE, Cunningham D, Chandler DS. SMN regulation in SMA and in response to stress: new paradigms and therapeutic possibilities. Hum Genet. 2017;136(9):1173–91. - DOI

LinkOut - more resources